-
Sihuan Biotechnology received a civil complaint involving three securities misrepresentation liability disputes
Time of Update: 2021-03-27
On March 20, Sihuan Biological issued an announcement stating that the company received a civil complaint and response from the Nanjing Intermediate People’s Court (2021) Su01 Minchu No.
, Kunshan Venture Holding Group Co.
, and Kunshan Venture Capital Co.
-
Pfizer's BRAF inhibitor approved in China for clinical treatment of colorectal cancer
Time of Update: 2021-03-27
According to the information on the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Pfizer's BRAF inhibitor encorafenib hard capsule has obtained an implied license for a clinical trial to develop a treatment for colorectal cancer.
-
The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States
Time of Update: 2021-03-27
Recently, the company announced that its targeted anticancer drug Pepaxto (melphalan flufenamide, also known as melflufen) has been included in the National Cancer Comprehensive Network (NCCN) clinical practice for multiple myeloma guide.
-
AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer
Time of Update: 2021-03-27
), used for maintenance treatment of patients with homologous recombination defect (HRD) positive advanced ovarian, fallopian tube and peritoneal cancer that fully or partially respond to first-line platinum-based chemotherapy and bevacizumab.
The US FDA approved the drug for use in advanced ovarian cancer with germline BRCA mutation (gBRCAm) that has received three or more chemotherapies.
-
New news from basic medicine
Time of Update: 2021-03-27
On the basis of the "Shandong Provincial Health Commission and Shandong Provincial Market Supervision Administration's Notice on Further Strengthening the Management of the Provision and Use of Essential Medicines in Public Medical Institutions", the proportion of essential medicines used will be further increased and the province's primary medical and health care will be promoted.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-03-27
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
When will the world's top 10 pharmaceutical companies have China? Ten questions about the future of China's innovative drugs, devices, and vaccines
Time of Update: 2021-03-27
Over the past ten years, we have experienced drug review reform, 722 self-examination, medical insurance reform, the opening of the Hong Kong stock market 18A and the science and technology innovation board, a large number of scientists returned to China to start businesses, and a number of outstanding innovative drug companies grew up.
-
BeiGene's CD3/CD19 dual-antibody new indications will be included in the priority review
Time of Update: 2021-03-27
Belinto Oumab was approved by the NMPA on December 4 last year through the priority review method for the treatment of adult relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).
-
Wu Huaifeng, director and secretary of the board of directors of Donge Ejiao, resigns
Time of Update: 2021-03-27
Due to personal reasons, Wu Huaifeng applied to resign as a director of the company, secretary of the board of directors and member of the audit committee of the board of directors.
After resignation, Wu Huaifeng will continue to serve as the company's senior vice president.
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-03-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
The heads of the Ministry of Justice, the State Administration of Market Supervision, and the Food and Drug Administration answer questions from reporters on the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-03-27
Question: In 2017, the Central Office and the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drugs and Medical Devices", proposing to promote the full implementation of the marketing authorization holder system.
-
Nefecon, a new drug for primary IgA nephropathy, applies for listing in the United States!
Time of Update: 2021-03-27
The Swedish biopharmaceutical company Calliditas Therapeutics recently announced that it has submitted a new drug application (NDA) for Nefecon (budesonide) to the US Food and Drug Administration (FDA), a new oral formulation that targets down-regulation of IgA1 for the treatment of primary IgA.
-
Pfizer's PF-06882961 clinical trial application was approved for the treatment of type 2 diabetes
Time of Update: 2021-03-27
Danuglipron (code name: PF-06882961 tablets) is an oral small molecule GLP-1 receptor agonist developed by Pfizer.
The company will also initiate a phase IIb clinical trial to test the efficacy of this oral small molecule GLP-1 receptor agonist in the treatment of patients with NASH.
-
A wholly-owned subsidiary of Tus Pharmaceuticals obtained the "Drug Production License"
Time of Update: 2021-03-27
The solid comprehensive preparation workshop and comprehensive extraction workshop production line involved in some of the fund-raising projects implemented by the Chinese Medicine Company have passed the on-site inspection of drug GMP compliance by the Hunan Provincial Drug Administration, and completed the modification record of the "Drug Production License".
-
Avitinib is out? Vometinib may become the second domestic third-generation EGFR-TKI
Time of Update: 2021-03-27
Avitinib, who was expected to win the title of "the first domestically produced third-generation EGFR-TKI", was overtaken by Amitinib and missed the first one.
It is still unknown who will become the second domestically produced third-generation EGFR-TKI on the market.
-
Generic Drugs | The second domestic Chenxin Pharmaceutical Teriflunomide Generic Drug Application for Production
Time of Update: 2021-03-27
In China, teriflunomide was approved by the NMPA for the treatment of relapsing MS in July 2018, and its trade name is Aubage, becoming the first oral DMT drug approved for marketing in my country.
-
Two exclusive formulations of 600 million anti-allergic drug companies have been reviewed
Time of Update: 2021-03-27
Brand pattern of the terminal desloratadine in China's public medical institutions in 2019Source: Mi Nei. com, China's public medical institutions terminal competition patternThe desloratadine products currently on the market in China include desloratadine tablets, desloratadine dispersible tablets, desloratadine dry suspension, desloratadine capsules, desloratadine syrup and Deloratadine oral solution.
-
The first Claudin 18.2/PD-L1 double antibody was approved for clinical use
Time of Update: 2021-03-27
Q-1802 is a bispecific antibody that is independently developed by Qiyu Biologics using its antibody engineering technology platform and has independent intellectual property rights that can simultaneously target PD-L1 and Claudin 18.
2/PD-L1 bispecific antibody that passed the US FDA IND.
-
Vertex begins Phase 1/2 clinical trial of VX-880 experimental treatment
Time of Update: 2021-03-27
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
-
CCTV Exposure: The price of Chinese medicine has risen again
Time of Update: 2021-03-27
cn/" target="_blank"> and regulations In addition, the publication of higher standards of the new version of the Pharmacopoeia is also conducive to the development of medicinal materials e-commerce.
